World

Ukraine tycoon Ihor Kolomoisky named suspect in fraud probe

Sep 03, 2023

Kyiv [Ukraine], September 3: A Ukrainian court ordered tycoon Ihor Kolomoisky to be held in custody for two months on suspicion of fraud and money laundering on Saturday, a striking move against one of the country's most powerful businessmen.
The detention of Kolomoisky, who is under U.S. sanctions and is a one-time supporter of President Volodymyr Zelenskiy whose election he backed in 2019, comes as Kyiv is trying to signal progress during a wartime crackdown on corruption.
Defence lawyers said Kolomoisky would appeal the ruling, questioning its legality, but that he would not post bail of almost $14 million in order to secure his release, broadcaster Radio Liberty reported.
After a hearing at a district court in Kyiv late on Saturday, Kolomoisky, one of Ukraine's richest men, was shown being led away in a blue tracksuit jacket in television footage. He could not be reached for comment.
The Security Service of Ukraine announced the case against Kolomoisky on Saturday morning, publishing photographs on Telegram Messenger showing him being served documents by security officers and signing them.
"It was established that during 2013-2020, Ihor Kolomoisky legalized more than half a billion hryvnias ($14 million) by withdrawing them abroad and using the infrastructure of banks under (his) control," the agency said in a statement.
After the ruling, Zelenskiy appeared to allude obliquely to the case in his evening address, thanking law enforcement agencies for showing resolve in bringing long-running cases to justice.
"Without a doubt, there will be no more decades-long 'business as usual' for those who plundered Ukraine and put themselves above the law and any rules. The law must work," he said.
Source: Fijian Broadcasting Corporation

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025